Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

CircRNAs: A Novel Strategy in Diagnosis and Treatment of Thyroid Cancer

Author(s): Rana Shafabakhsh, Zatollah Asemi*, Mohammad Ali Mansournia, Bahman Yousefi and Jamal Hallajzadeh*

Volume 23, Issue 8, 2023

Published on: 27 August, 2022

Page: [737 - 747] Pages: 11

DOI: 10.2174/1566524022666220701141914

Price: $65

Abstract

Thyroid cancer is one of the most frequent cancers globally, and its incidence has risen recently. The clinical behavior of thyroid cancer includes a wide range, from benign to invasive malignant tumors. Thus, precious diagnostic activities before therapeutic work are required. Circular RNAs (circRNAs) along with microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are known as non-coding RNAs (ncRNAs). Large amounts of investigations have indicated that circRNAs can participate in multiple cellular processes, especially in tumorigenesis. Furthermore, circRNAs are stable in blood or plasma, as well as they are specific in different tissues. Therefore, they could serve as a potential diagnostic biomarker for cancer cells. Limited studies investigated the role of circRNAs in some processes involved in thyroid cancer. In this review, we summarized the current evidence on the potential clinical involvement of circRNAs in thyroid cancer.

Keywords: CircRNAs, apoptosis, microRNA, signaling pathway, thyroid cancer, neuroendocrine cell.

« Previous Next »
[1]
Durante C, Costante G, Lucisano G, et al. The natural history of benign thyroid nodules. JAMA 2015; 313(9): 926-35.
[http://dx.doi.org/10.1001/jama.2015.0956] [PMID: 25734734]
[2]
Dralle H, Machens A, Basa J, et al. Follicular cell-derived thyroid cancer. Nat Rev Dis Primers 2015; 1: 15077.
[http://dx.doi.org/10.1038/nrdp.2015.77] [PMID: 27188261]
[3]
Caron NR, Clark OH. Papillary thyroid cancer. Curr Treat Options Oncol 2006; 7(4): 309-19.
[http://dx.doi.org/10.1007/s11864-006-0040-7] [PMID: 16916491]
[4]
Grimm D. Current knowledge in thyroid cancer-from bench to bedside. Int J Mol Sci 2017; 18(7): E1529.
[http://dx.doi.org/10.3390/ijms18071529] [PMID: 28714875]
[5]
Shah JP. Thyroid carcinoma: Epidemiology, histology, and diagnosis. Clin Adv Hematol Oncol 2015; 13(4 Suppl): 3-6.
[6]
Cote GJ, Grubbs EG, Hofmann MC. Thyroid C-cell biology and oncogenic transformation. Recent Results Cancer Res 2015; 204: 1-39.
[http://dx.doi.org/10.1007/978-3-319-22542-5_1] [PMID: 26494382]
[7]
Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25(6): 567-610.
[http://dx.doi.org/10.1089/thy.2014.0335]
[8]
Moley JF. Medullary thyroid carcinoma: Management of lymph node metastases. J Natl Compr Canc Netw 2010; 8(5): 549-56.
[http://dx.doi.org/10.6004/jnccn.2010.0042] [PMID: 20495084]
[9]
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646-74.
[http://dx.doi.org/10.1016/j.cell.2011.02.013] [PMID: 21376230]
[10]
Raman P, Koenig RJ. Pax-8-PPAR-γ fusion protein in thyroid carcinoma. Nat Rev Endocrinol 2014; 10(10): 616-23.
[http://dx.doi.org/10.1038/nrendo.2014.115] [PMID: 25069464]
[11]
Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011; 7(10): 569-80.
[http://dx.doi.org/10.1038/nrendo.2011.142] [PMID: 21878896]
[12]
Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: From clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol 2017; 13(11): 644-60.
[http://dx.doi.org/10.1038/nrendo.2017.76] [PMID: 28707679]
[13]
Smolle E, Haybaeck J. Non-coding RNAs and lipid metabolism. Int J Mol Sci 2014; 15(8): 13494-513.
[http://dx.doi.org/10.3390/ijms150813494] [PMID: 25093715]
[14]
Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013; 495(7441): 333-8.
[http://dx.doi.org/10.1038/nature11928] [PMID: 23446348]
[15]
Lambertini M, Santoro L, Del Mastro L, et al. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. Cancer Treat Rev 2016; 49: 65-76.
[http://dx.doi.org/10.1016/j.ctrv.2016.07.006] [PMID: 27529149]
[16]
Bach DH, Lee SK, Sood AK. Circular RNAs in Cancer. Mol Ther Nucleic Acids 2019; 16: 118-29.
[http://dx.doi.org/10.1016/j.omtn.2019.02.005] [PMID: 30861414]
[17]
Song L, Xiao Y. Downregulation of hsa_circ_0007534 suppresses breast cancer cell proliferation and invasion by targeting miR-593/MUC19 signal pathway. Biochem Biophys Res Commun 2018; 503(4): 2603-10.
[http://dx.doi.org/10.1016/j.bbrc.2018.08.007] [PMID: 30139516]
[18]
Chen G, Wang Q, Yang Q, et al. Circular RNAs hsa_circ_0032462, hsa_circ_0028173, hsa_circ_0005909 are predicted to promote CADM1 expression by functioning as miRNAs sponge in human osteosarcoma. PLoS One 2018; 13(8): e0202896.
[19]
Wang L, Wei Y, Yan Y, et al. CircDOCK1 suppresses cell apoptosis via inhibition of miR-196a-5p by targeting BIRC3 in OSCC. Oncol Rep 2018; 39(3): 951-66.
[PMID: 29286141]
[20]
Yin Y, Long J, He Q, et al. Emerging roles of circRNA in formation and progression of cancer. J Cancer 2019; 10(21): 5015-21.
[http://dx.doi.org/10.7150/jca.30828] [PMID: 31602252]
[21]
Pan H, Li T, Jiang Y, et al. Overexpression of circular RNA ciRS-7 abrogates the tumor suppressive effect of miR-7 on gastric cancer via PTEN/PI3K/AKT signaling pathway. J Cell Biochem 2018; 119(1): 440-6.
[http://dx.doi.org/10.1002/jcb.26201] [PMID: 28608528]
[22]
Memczak S, Papavasileiou P, Peters O, Rajewsky N. Identification and characterization of circular RNAs as a new class of putative biomarkers in human blood. PLoS One 2015; 10(10): e0141214.
[http://dx.doi.org/10.1371/journal.pone.0141214] [PMID: 26485708]
[23]
Cocquerelle C, Mascrez B, Hétuin D, Bailleul B. Mis-splicing yields circular RNA molecules. FASEB J 1993; 7(1): 155-60.
[http://dx.doi.org/10.1096/fasebj.7.1.7678559] [PMID: 7678559]
[24]
Chen I, Chen CY, Chuang TJ. Biogenesis, identification, and function of exonic circular RNAs. Wiley Interdiscip Rev RNA 2015; 6(5): 563-79.
[http://dx.doi.org/10.1002/wrna.1294] [PMID: 26230526]
[25]
Westholm JO, Miura P, Olson S, et al. Genome-wide analysis of drosophila circular RNAs reveals their structural and sequence properties and age-dependent neural accumulation. Cell Rep 2014; 9(5): 1966-80.
[http://dx.doi.org/10.1016/j.celrep.2014.10.062] [PMID: 25544350]
[26]
Zhang XO, Dong R, Zhang Y, et al. Diverse alternative back-splicing and alternative splicing landscape of circular RNAs. Genome Res 2016; 26(9): 1277-87.
[http://dx.doi.org/10.1101/gr.202895.115] [PMID: 27365365]
[27]
Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA 2013; 19(2): 141-57.
[http://dx.doi.org/10.1261/rna.035667.112] [PMID: 23249747]
[28]
Zhang Y, Zhang XO, Chen T, et al. Circular intronic long noncoding RNAs. Mol Cell 2013; 51(6): 792-806.
[http://dx.doi.org/10.1016/j.molcel.2013.08.017] [PMID: 24035497]
[29]
Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol 2015; 22(3): 256-64.
[http://dx.doi.org/10.1038/nsmb.2959] [PMID: 25664725]
[30]
Lu Z, Filonov GS, Noto JJ, et al. Metazoan tRNA introns generate stable circular RNAs in vivo. RNA 2015; 21(9): 1554-65.
[http://dx.doi.org/10.1261/rna.052944.115] [PMID: 26194134]
[31]
Kohlhapp FJ, Mitra AK, Lengyel E, Peter ME. MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene 2015; 34(48): 5857-68.
[http://dx.doi.org/10.1038/onc.2015.89] [PMID: 25867073]
[32]
Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature 2013; 495(7441): 384-8.
[http://dx.doi.org/10.1038/nature11993] [PMID: 23446346]
[33]
Guo JU, Agarwal V, Guo H, Bartel DP. Expanded identification and characterization of mammalian circular RNAs. Genome Biol 2014; 15(7): 409.
[http://dx.doi.org/10.1186/s13059-014-0409-z] [PMID: 25070500]
[34]
Thomas LF, Sætrom P. Circular RNAs are depleted of polymorphisms at microRNA binding sites. Bioinformatics 2014; 30(16): 2243-6.
[http://dx.doi.org/10.1093/bioinformatics/btu257] [PMID: 24764460]
[35]
Hsiao KY, Lin YC, Gupta SK, et al. Noncoding Effects of Circular RNA CCDC66 Promote Colon Cancer Growth and Metastasis. Cancer Res 2017; 77(9): 2339-50.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-1883] [PMID: 28249903]
[36]
Boeckel JN, Jaé N, Heumüller AW, et al. Identification and Characterization of Hypoxia-Regulated Endothelial Circular RNA. Circ Res 2015; 117(10): 884-90.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.306319] [PMID: 26377962]
[37]
Panda AC, Grammatikakis I, Kim KM, et al. Identification of Senescence-Associated Circular RNAs (SAC-RNAs) reveals senescence suppressor CircPVT1. Nucleic Acids Res 2017; 45(7): 4021-35.
[http://dx.doi.org/10.1093/nar/gkw1201] [PMID: 27928058]
[38]
Li F, Zhang L, Li W, et al. Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/β-catenin pathway. Oncotarget 2015; 6(8): 6001-13.
[http://dx.doi.org/10.18632/oncotarget.3469] [PMID: 25749389]
[39]
Ashwal-Fluss R, Meyer M, Pamudurti NR, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell 2014; 56(1): 55-66.
[http://dx.doi.org/10.1016/j.molcel.2014.08.019] [PMID: 25242144]
[40]
Abdelmohsen K, Panda AC, Munk R, et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol 2017; 14(3): 361-9.
[http://dx.doi.org/10.1080/15476286.2017.1279788] [PMID: 28080204]
[41]
Lebedeva S, Jens M, Theil K, et al. Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR. Mol Cell 2011; 43(3): 340-52.
[http://dx.doi.org/10.1016/j.molcel.2011.06.008] [PMID: 21723171]
[42]
Guarnerio J, Bezzi M, Jeong JC, et al. Oncogenic role of fusion-circRNAs derived from cancer-associated chromosomal translocations. Cell 2016; 166(4): 1055-6.
[http://dx.doi.org/10.1016/j.cell.2016.07.035] [PMID: 27518567]
[43]
Du WW, Yang W, Chen Y, et al. Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses. Eur Heart J 2017; 38(18): 1402-12.
[PMID: 26873092]
[44]
Du WW, Yang W, Liu E, Yang Z, Dhaliwal P, Yang BB. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res 2016; 44(6): 2846-58.
[http://dx.doi.org/10.1093/nar/gkw027] [PMID: 26861625]
[45]
Chen CY, Sarnow P. Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs. Science 1995; 268(5209): 415-7.
[http://dx.doi.org/10.1126/science.7536344] [PMID: 7536344]
[46]
Legnini I, Di Timoteo G, Rossi F, et al. Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis. Mol Cell 2017; 66(1): 22-37.e9.
[http://dx.doi.org/10.1016/j.molcel.2017.02.017] [PMID: 28344082]
[47]
Draz MS, Fang BA, Zhang P, et al. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics 2014; 4(9): 872-92.
[http://dx.doi.org/10.7150/thno.9404] [PMID: 25057313]
[48]
Williford JM, Wu J, Ren Y, Archang MM, Leong KW, Mao HQ. Recent advances in nanoparticle-mediated siRNA delivery. Annu Rev Biomed Eng 2014; 16: 347-70.
[http://dx.doi.org/10.1146/annurev-bioeng-071813-105119] [PMID: 24905873]
[49]
Awan FM, Yang BB, Naz A, et al. The emerging role and significance of circular RNAs in viral infections and antiviral immune responses: Possible implication as theranostic agents. RNA Biol 2021; 18(1): 1-15.
[http://dx.doi.org/10.1080/15476286.2020.1790198] [PMID: 32615049]
[50]
Yang W, Du WW, Li X, Yee AJ, Yang BB. Foxo3 activity promoted by non-coding effects of circular RNA and Foxo3 pseudogene in the inhibition of tumor growth and angiogenesis. Oncogene 2016; 35(30): 3919-31.
[http://dx.doi.org/10.1038/onc.2015.460] [PMID: 26657152]
[51]
Meganck RM, Borchardt EK, Castellanos Rivera RM, et al. Tissue-dependent expression and translation of circular RNAs with recombinant AAV vectors in vivo. Mol Ther Nucleic Acids 2018; 13: 89-98.
[http://dx.doi.org/10.1016/j.omtn.2018.08.008] [PMID: 30245471]
[52]
Müller S, Appel B. In vitro circularization of RNA. RNA Biol 2017; 14(8): 1018-27.
[http://dx.doi.org/10.1080/15476286.2016.1239009] [PMID: 27668458]
[53]
Chen YG, Chen R, Ahmad S, et al. N6-methyladenosine modification controls circular RNA immunity. Mol Cell 2019; 76(1): 96-109.
[http://dx.doi.org/10.1016/j.molcel.2019.07.016]
[54]
Holdt LM, Kohlmaier A, Teupser D. Circular RNAs as therapeutic agents and targets. Front Physiol 2018; 9: 1262.
[http://dx.doi.org/10.3389/fphys.2018.01262] [PMID: 30356745]
[55]
Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012; 63: 185-98.
[http://dx.doi.org/10.1146/annurev-med-040210-162544] [PMID: 21888516]
[56]
Ma X, Zhao Y, Liang XJ. Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc Chem Res 2011; 44(10): 1114-22.
[http://dx.doi.org/10.1021/ar2000056] [PMID: 21732606]
[57]
Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater 2013; 12(11): 991-1003.
[http://dx.doi.org/10.1038/nmat3776] [PMID: 24150417]
[58]
Chen L, Watson C, Morsch M, et al. Improving the delivery of SOD1 antisense oligonucleotides to motor neurons using calcium phosphate-lipid nanoparticles. Front Neurosci 2017; 11: 476.
[http://dx.doi.org/10.3389/fnins.2017.00476] [PMID: 28912673]
[59]
Oliveira ACN, Fernandes J, Gonçalves A, Gomes AC, Oliveira MECDR. Lipid-based nanocarriers for siRNA delivery: Challenges, strategies and the lessons learned from the DODAX: MO liposomal system. Curr Drug Targets 2019; 20(1): 29-50.
[http://dx.doi.org/10.2174/1389450119666180703145410] [PMID: 29968536]
[60]
Kulkarni JA, Witzigmann D, Chen S, Cullis PR, van der Meel R. Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Acc Chem Res 2019; 52(9): 2435-44.
[http://dx.doi.org/10.1021/acs.accounts.9b00368] [PMID: 31397996]
[61]
Shi X, Wang B, Feng X, Xu Y, Lu K, Sun M. circRNAs and exosomes: A mysterious frontier for human cancer. Mol Ther Nucleic Acids 2020; 19: 384-92.
[http://dx.doi.org/10.1016/j.omtn.2019.11.023] [PMID: 31887549]
[62]
Xiong S, Peng H, Ding X, et al. Circular RNA Expression Profiling and the Potential Role of hsa_circ_0089172 in Hashimoto’s Thyroiditis via Sponging miR125a-3p. Mol Ther Nucleic Acids 2019; 17: 38-48.
[http://dx.doi.org/10.1016/j.omtn.2019.05.004] [PMID: 31207490]
[63]
Liang G, Yang Y, Niu G, Tang Z, Li K. Genome-wide profiling of Sus scrofa circular RNAs across nine organs and three developmental stages. DNA Res 2017; 24(5): 523-35.
[http://dx.doi.org/10.1093/dnares/dsx022] [PMID: 28575165]
[64]
Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol 2014; 32(5): 453-61.
[http://dx.doi.org/10.1038/nbt.2890] [PMID: 24811520]
[65]
Salzman J, Chen RE, Olsen MN, Wang PL, Brown PO. Cell-type specific features of circular RNA expression. PLoS Genet 2013; 9(9): e1003777.
[http://dx.doi.org/10.1371/journal.pgen.1003777] [PMID: 24039610]
[66]
Zhao W, Cheng Y, Zhang C, et al. Genome-wide identification and characterization of circular RNAs by high throughput sequencing in soybean. Sci Rep 2017; 7(1): 5636.
[http://dx.doi.org/10.1038/s41598-017-05922-9] [PMID: 28717203]
[67]
Xing M. Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am 2008; 41(6): 1135-46. ix.
[http://dx.doi.org/10.1016/j.otc.2008.07.001] [PMID: 19040974]
[68]
Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 2011; 71(13): 4403-11.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-4041] [PMID: 21596819]
[69]
Hou P, Liu D, Xing M. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer 2011; 18(6): 687-97.
[http://dx.doi.org/10.1530/ERC-11-0212] [PMID: 21937738]
[70]
Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 2006; 91(9): 3667-70.
[http://dx.doi.org/10.1210/jc.2005-2836] [PMID: 16772349]
[71]
Kumagai A, Namba H, Mitsutake N, et al. Childhood thyroid carcinoma with BRAFT1799A mutation shows unique pathological features of poor differentiation. Oncol Rep 2006; 16(1): 123-6.
[http://dx.doi.org/10.3892/or.16.1.123] [PMID: 16786134]
[72]
Palona I, Namba H, Mitsutake N, et al. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 2006; 147(12): 5699-707.
[http://dx.doi.org/10.1210/en.2006-0400] [PMID: 16959844]
[73]
Mesa C Jr, Mirza M, Mitsutake N, et al. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 2006; 66(13): 6521-9.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-0739] [PMID: 16818623]
[74]
Franzoni A, Dima M, D'Agostino M, et al. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. Thyroid 2009; 19(3): 247-55.
[75]
Watanabe R, Hayashi Y, Sassa M, et al. Possible involvement of BRAFV600E in altered gene expression in papillary thyroid cancer. Endocr J 2009; 56(3): 407-14.
[http://dx.doi.org/10.1507/endocrj.K08E-329] [PMID: 19194051]
[76]
Zerilli M, Zito G, Martorana A, et al. BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer. Mod Pathol 2010; 23(8): 1052-60.
[77]
Pasquali D, Santoro A, Bufo P, et al. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation. Thyroid 2011; 21(4): 391-9.
[http://dx.doi.org/10.1089/thy.2010.0168]
[78]
Nowicki TS, Zhao H, Darzynkiewicz Z, et al. Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle 2011; 10(1): 100-7.
[http://dx.doi.org/10.4161/cc.10.1.14362] [PMID: 21191179]
[79]
Nucera C, Porrello A, Antonello ZA, et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA 2010; 107(23): 10649-54.
[http://dx.doi.org/10.1073/pnas.1004934107] [PMID: 20498063]
[80]
Ringel MD, Hayre N, Saito J, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001; 61(16): 6105-11.
[PMID: 11507060]
[81]
Vasko V, Saji M, Hardy E, et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 2004; 41(3): 161-70.
[http://dx.doi.org/10.1136/jmg.2003.015339] [PMID: 14985374]
[82]
Abbosh PH, Nephew KP. Multiple signaling pathways converge on beta-catenin in thyroid cancer. Thyroid 2005; 15(6): 551-61.
[83]
Pacifico F, Mauro C, Barone C, et al. Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 2004; 279(52): 54610-9.
[http://dx.doi.org/10.1074/jbc.M403492200] [PMID: 15475567]
[84]
Oh HJ, Lee KK, Song SJ, et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res 2006; 66(5): 2562-9.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-2951] [PMID: 16510573]
[85]
Xing M, Cohen Y, Mambo E, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 2004; 64(5): 1664-8.
[http://dx.doi.org/10.1158/0008-5472.CAN-03-3242] [PMID: 14996725]
[86]
Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 2012; 149(6): 1192-205.
[http://dx.doi.org/10.1016/j.cell.2012.05.012] [PMID: 22682243]
[87]
Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. Beta-catenin dysregulation in thyroid neoplasms: Down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 2001; 158(3): 987-96.
[http://dx.doi.org/10.1016/S0002-9440(10)64045-X] [PMID: 11238046]
[88]
Castellone MD, De Falco V, Rao DM, et al. The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res 2009; 69(5): 1867-76.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-1982] [PMID: 19223551]
[89]
Burrows N, Resch J, Cowen RL, et al. Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas. Endocr Relat Cancer 2010; 17(1): 61-72.
[http://dx.doi.org/10.1677/ERC-08-0251] [PMID: 19808899]
[90]
Bi W, Huang J, Nie C, et al. CircRNA circRNA_102171 promotes papillary thyroid cancer progression through modulating CTNNBIP1-dependent activation of β-catenin pathway. J Exp Clin Cancer Res 2018; 37(1): 275.
[http://dx.doi.org/10.1186/s13046-018-0936-7] [PMID: 30424816]
[91]
Chen F, Feng Z, Zhu J, et al. Emerging roles of circRNA_NEK6 targeting miR-370-3p in the proliferation and invasion of thyroid cancer via Wnt signaling pathway. Cancer Biol Ther 2018; 19(12): 1139-52.
[http://dx.doi.org/10.1080/15384047.2018.1480888] [PMID: 30207869]
[92]
Ye M, Hou H, Shen M, Dong S, Zhang T. Circular RNA circFOXM1 Plays a Role in Papillary Thyroid Carcinoma by Sponging miR-1179 and Regulating HMGB1 Expression. Mol Ther Nucleic Acids 2020; 19: 741-50.
[http://dx.doi.org/10.1016/j.omtn.2019.12.014] [PMID: 31951855]
[93]
Zhang H, Ma XP, Li X, Deng FS. Circular RNA circ_0067934 exhaustion expedites cell apoptosis and represses cell proliferation, migration and invasion in thyroid cancer via sponging miR-1304 and regulating CXCR1 expression. Eur Rev Med Pharmacol Sci 2019; 23(24): 10851-66.
[PMID: 31858554]
[94]
Yao Y, Chen X, Yang H, et al. Hsa_circ_0058124 promotes papillary thyroid cancer tumorigenesis and invasivenessthrough the NOTCH3/GATAD2A axis. 2019; 38(1): 318.
[95]
Yang Y, Ding L, Li Y, Xuan C. Hsa_circ_0039411 promotes tumorigenesis and progression of papillary thyroid cancer by miR-1179/ABCA9 and miR-1205/MTA1 signaling pathways. 2020; 235(2): 1321-9.
[96]
Liu W, Zhao J, Jin M, Zhou M. circRAPGEF5 contributes to papillary thyroid proliferation and metastatis by regulation miR-198/FGFR1. Mol Ther Nucleic Acids 2019; 14: 609-16.
[http://dx.doi.org/10.1016/j.omtn.2019.01.003] [PMID: 30785065]
[97]
Wang H, Yan X, Zhang H, Zhan X. CircRNA circ_0067934 overexpression correlates with poor prognosis and promotes thyroid carcinoma progression. Med Sci Monit 2019; 25: 1342-9.
[http://dx.doi.org/10.12659/MSM.913463] [PMID: 30779728]
[98]
Pan Y, Xu T, Liu Y, Li W, Zhang W. Upregulated circular RNA circ_0025033 promotes papillary thyroid cancer cell proliferation and invasion via sponging miR-1231 and miR-1304. Biochem Biophys Res Commun 2019; 510(2): 334-8.
[http://dx.doi.org/10.1016/j.bbrc.2019.01.108] [PMID: 30709584]
[99]
Liu F, Zhang J, Qin L, et al. Circular RNA EIF6 (Hsa_circ_0060060) sponges miR-144-3p to promote the cisplatin-resistance of human thyroid carcinoma cells by autophagy regulation. Aging (Albany NY) 2018; 10(12): 3806-20.
[http://dx.doi.org/10.18632/aging.101674] [PMID: 30540564]
[100]
Li X, Tian Y, Hu Y, Yang Z, Zhang L, Luo J. CircNUP214 sponges miR-145 to promote the expression of ZEB2 in thyroid cancer cells. Biochem Biophys Res Commun 2018; 507(1-4): 168-72.
[http://dx.doi.org/10.1016/j.bbrc.2018.10.200] [PMID: 30415780]
[101]
Jin X, Wang Z, Pang W, et al. Upregulated hsa_circ_0004458 contributes to progression of papillary thyroid carcinoma by inhibition of miR-885-5p and activation of RAC1. Med Sci Monit 2018; 24: 5488-500.
[http://dx.doi.org/10.12659/MSM.911095] [PMID: 30086127]
[102]
Wei H, Pan L, Tao D, Li R. Circular RNA circZFR contributes to papillary thyroid cancer cell proliferation and invasion by sponging miR-1261 and facilitating C8orf4 expression. Biochem Biophys Res Commun 2018; 503(1): 56-61.
[http://dx.doi.org/10.1016/j.bbrc.2018.05.174] [PMID: 29842886]
[103]
Wang M, Chen B, Ru Z, Cong L. CircRNA circ-ITCH suppresses papillary thyroid cancer progression through miR-22-3p/CBL/β-catenin pathway. Biochem Biophys Res Commun 2018; 504(1): 283-8.
[http://dx.doi.org/10.1016/j.bbrc.2018.08.175] [PMID: 30190130]
[104]
Lan X, Cao J, Xu J, et al. Decreased expression of hsa_circ_0137287 predicts aggressive clinicopathologic characteristics in papillary thyroid carcinoma. J Clin Lab Anal 2018; 32(8): e22573.
[http://dx.doi.org/10.1002/jcla.22573] [PMID: 29790216]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy